| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Sarraf Pasha serves as a Director at CUE. Across recent SEC filings that breaks down to 5 buys and 0 sells. Those positions are worth an estimated $884K at current prices.
The biggest single holding is CUE (~$884K) as Director. Net of sales, the recent Form 4 record there shows accumulation of 323,857 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 30, 2025 | CUE Cue Biopharma, Inc. | Director | Buy | 323,857 | $0.31 | $99,747.26 | +64.7% | -25.3% | - |